论文部分内容阅读
目的观察小剂量阿托伐他汀治疗动脉硬化的临床疗效。方法 2014年3月—2015年3月收治的100例动脉硬化患者,按随机数字表法分为观察组和对照组,每组50例。对照组患者给予常规治疗,观察组患者在对照组治疗的基础上加以小剂量阿托伐他汀口服,比较两组治疗后的总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、脉搏波传导速度(ba PWV)、颈动脉内膜中层厚度(IMT)、不良反应情况等。结果观察组治疗后的TC、HDL-C、LDL-C、TG、ba PWV、IMT指标均明显优于治疗前(P<0.05),且与对照组比较差异显著(P<0.05);对照组治疗后的各项指标较治疗前均无明显变化(P>0.05);观察组与对照组不良反应率比较无明显差异(P>0.05)。结论小剂量的阿托伐他汀在动脉硬化治疗中疗效确切,不良反应发生率低,是一种安全有效的治疗药物,值得临床推广和应用。
Objective To observe the clinical efficacy of low-dose atorvastatin in the treatment of atherosclerosis. Methods From March 2014 to March 2015, 100 patients with atherosclerosis were divided into observation group and control group according to random number table method, with 50 cases in each group. Patients in the control group were treated with atorvastatin in a small dose on the basis of the treatment of the control group. The levels of total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low (LDL-C), triglyceride (TG), pulse wave velocity (ba PWV), carotid intima-media thickness (IMT), adverse reactions and so on. Results The levels of TC, HDL-C, LDL-C, TG, ba PWV and IMT in observation group were significantly better than those before treatment (P <0.05), and were significantly different from those in control group There was no significant difference between the two groups after treatment (P> 0.05). There was no significant difference in adverse reaction rate between the observation group and the control group (P> 0.05). Conclusions Atorvastatin in low dose is effective in treating arteriosclerosis and has a low incidence of adverse reactions. It is a safe and effective therapeutic drug and is worthy of clinical promotion and application.